GLP-1 coverage in California

Coverage is not only cheaper, it means the prescription sits inside your medical care rather than alongside it. Here is where California stands.

California eliminated Medicaid coverage of GLP-1s for obesity treatment.

California was one of four states — alongside New Hampshire, Pennsylvania and South Carolina — that eliminated Medi-Cal coverage of GLP-1s for obesity treatment after October 2025, a change KFF attributes to state budget pressure and the cost of the drugs. If you were previously covered in California for weight management, that route has closed. Everything below is sourced — we are not going to tell you what a California clinic charges, because every provider we track is 50-state telehealth and prices the same wherever you live. What actually differs by state is coverage, and that is what this page is about.

Why coverage changes the care, not just the cost

A covered prescription usually sits inside your existing medical relationship, with your own clinician managing dose changes and side effects. A cash-pay telehealth programme sits alongside it. At the doses and ages our readers are dealing with, that difference matters beyond the money.

Medicaid and GLP-1s in California

Coverage for obesity is optional for states — the national picture is on our coverage index. Here is where California sits.

If you are on Medicaid in California

What to do in California: If you were on a covered GLP-1 through Medi-Cal before the change, do not simply stop — talk to your prescriber about whether you qualify under a diabetes, cardiovascular or sleep apnea indication, because those remain mandatory.

Coverage for type 2 diabetes, cardiovascular disease and sleep apnea is mandatory everywhere, so a refusal framed around weight loss is not the end of it — and on Medicare, the $50 programme starts 1 July 2026 regardless of which state you are in.

California: common questions

Did Medi-Cal stop covering Ozempic and Wegovy entirely?

Not entirely. California eliminated coverage of GLP-1s for obesity treatment. Coverage for type 2 diabetes remains mandatory under federal rules, as does coverage for cardiovascular disease and sleep apnea indications. What ended was the weight-management route.

I am mid-treatment on Medi-Cal. What happens now?

Speak to your prescriber before your next refill rather than after it. If you have a qualifying diagnosis the prescription may continue under a different indication; if not, you need a plan rather than an interruption, because restarting at your old dose after a gap is unsafe.

Sources: KFF, “Medicaid Coverage of and Spending on GLP-1s”, 16 January 2026; CDC Adult Obesity Prevalence Maps, 2024 data, published 3 December 2025. Verified 2026-09-18. Coverage positions change mid-year — confirm yours with your plan. Not medical, legal or benefits advice.